# FDA 483 - Piedmont Reproductive Endocrinology Group, Pa - January 21, 2026

Source: https://www.keypedia.com/records/483/piedmont-reproductive-endocrinology-group-pa/39d5c76d-2a01-4481-a76d-88010c12d2fb

> FDA 483 for Piedmont Reproductive Endocrinology Group, Pa on January 21, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Piedmont Reproductive Endocrinology Group, Pa
- Inspection Date: 2026-01-21
- Product Type: biologics
- Office Name: FDA District Office — Atlanta, Georgia
- Summary: Piedmont Reproductive Endocrinology Group, Pa in Greenville, SC was inspected by the FDA from January 16-21, 2026. The inspection revealed a significant issue regarding donor screening procedures for anonymous oocyte donors. The firm failed to perform complete physical examinations within the required six-month timeframe, instead using abbreviated screening methods, which led to the use of oocytes from inadequately screened donors.

## Related Officers

- [Richard J. Bashay](https://www.keypedia.com/people/richard-j-bashay/ce50702d-1f5b-42c5-b50a-88bb43cba196)

Company: https://www.keypedia.com/companies/piedmont-reproductive-endocrinology-group-pa/b2ee7cdb-2340-42b8-9f2d-d3e318b64d0b

Office: https://www.keypedia.com/offices/fda-district-office-atlanta-georgia/bae3b8c4-4161-4e9f-b5d1-e0e80b6abd43